Do you think the Army are going to sit up after these results?
Re NNZ-2591 from AGM Presentation...
We have recently entered into a new CRADA with the neurosciences group at WRAIR to assess the effects of orally administered NNZ-2592 on mTOR (a key molecular pathway involved in neuroplasticity and neurite outgrowth that plays a significant role in Rett and Fragile X Syndromes), on the histopathology of neurogenesis and neuroplasticity and on serum-biomarkers of protein expression and activation. The Army also will identify the pathways which are regulated by NNZ-2592 including neuroinflammatoru cytokines and pro- and anti-apoptotic genes.
As I have posted, it was WRAIR who conducted much of the ground-breaking work to define the pharmacology and mechanisms of action of NNZ-2566, Neuren's lead clinical candidate. Good track record to date. Sure, more work to do, but the data is certainly looking 'overwhelmingly positive' don't you think?
Neuren have just turned this up a notch, with plenty more to go.
Exciting stuff!
Tony
NEU Price at posting:
10.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)